Cargando…
Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study
OBJECTIVES: This study aims to test the feasibility of the Fracture and Mortality Risk Evaluation (FAME) Index. PATIENTS AND METHODS: Two academic centers in Lithuania and Turkey participated in this retrospective study conducted between November 2018 and July 2019. A total of 100 consecutive patien...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bayçınar Medical Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489183/ https://www.ncbi.nlm.nih.gov/pubmed/32315279 http://dx.doi.org/10.5606/ehc.2020.73458 |
_version_ | 1783581833428992000 |
---|---|
author | Sezgin, Erdem Aras Markevičiūtė, Vėtra Širka, Aurimas Tarasevičius, Šarūnas Bushan Raina, Deepak Isaksson, Hanna Tägil, Magnus Lidgren, Lars |
author_facet | Sezgin, Erdem Aras Markevičiūtė, Vėtra Širka, Aurimas Tarasevičius, Šarūnas Bushan Raina, Deepak Isaksson, Hanna Tägil, Magnus Lidgren, Lars |
author_sort | Sezgin, Erdem Aras |
collection | PubMed |
description | OBJECTIVES: This study aims to test the feasibility of the Fracture and Mortality Risk Evaluation (FAME) Index. PATIENTS AND METHODS: Two academic centers in Lithuania and Turkey participated in this retrospective study conducted between November 2018 and July 2019. A total of 100 consecutive patients (22 males, 78 females; mean age 78.9 years; range, 45 to 100 years) with low energy proximal femur fractures admitted for surgery were included in the study. Fracture Risk Assessment tool (FRAX) and the Sernbo scores were calculated and patients were classified into one of the nine subcategories of the FAME Index. RESULTS: Demographics and FAME Index classifications were similar between centers. Patients with high risk of fracture and low risk of mortality accounted for 18% of all patients, which is the FAME Index subcategory to theoretically benefit from cancellous bone augmentation during internal fixation of a fragility hip fracture the most. CONCLUSION: The FAME Index was successfully applied in clinical emergency setting utilizing a simple form, and demonstrated promising potential in stratification of hip fractures most suitable for screw and device augmentation. Larger studies with at least one-year of follow-up are warranted to verify the validity of FAME Index. |
format | Online Article Text |
id | pubmed-7489183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Bayçınar Medical Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74891832020-09-17 Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study Sezgin, Erdem Aras Markevičiūtė, Vėtra Širka, Aurimas Tarasevičius, Šarūnas Bushan Raina, Deepak Isaksson, Hanna Tägil, Magnus Lidgren, Lars Jt Dis Relat Surg Original Article OBJECTIVES: This study aims to test the feasibility of the Fracture and Mortality Risk Evaluation (FAME) Index. PATIENTS AND METHODS: Two academic centers in Lithuania and Turkey participated in this retrospective study conducted between November 2018 and July 2019. A total of 100 consecutive patients (22 males, 78 females; mean age 78.9 years; range, 45 to 100 years) with low energy proximal femur fractures admitted for surgery were included in the study. Fracture Risk Assessment tool (FRAX) and the Sernbo scores were calculated and patients were classified into one of the nine subcategories of the FAME Index. RESULTS: Demographics and FAME Index classifications were similar between centers. Patients with high risk of fracture and low risk of mortality accounted for 18% of all patients, which is the FAME Index subcategory to theoretically benefit from cancellous bone augmentation during internal fixation of a fragility hip fracture the most. CONCLUSION: The FAME Index was successfully applied in clinical emergency setting utilizing a simple form, and demonstrated promising potential in stratification of hip fractures most suitable for screw and device augmentation. Larger studies with at least one-year of follow-up are warranted to verify the validity of FAME Index. Bayçınar Medical Publishing 2020-04-11 /pmc/articles/PMC7489183/ /pubmed/32315279 http://dx.doi.org/10.5606/ehc.2020.73458 Text en Copyright © 2020, Turkish Joint Diseases Foundation http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Article Sezgin, Erdem Aras Markevičiūtė, Vėtra Širka, Aurimas Tarasevičius, Šarūnas Bushan Raina, Deepak Isaksson, Hanna Tägil, Magnus Lidgren, Lars Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study |
title | Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study |
title_full | Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study |
title_fullStr | Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study |
title_full_unstemmed | Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study |
title_short | Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study |
title_sort | combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: a feasibility study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489183/ https://www.ncbi.nlm.nih.gov/pubmed/32315279 http://dx.doi.org/10.5606/ehc.2020.73458 |
work_keys_str_mv | AT sezginerdemaras combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy AT markeviciutevetra combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy AT sirkaaurimas combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy AT taraseviciussarunas combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy AT bushanrainadeepak combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy AT isakssonhanna combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy AT tagilmagnus combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy AT lidgrenlars combinedfractureandmortalityriskevaluationforstratifyingtreatmentinhipfracturepatientsafeasibilitystudy |